Hereditary prostate cancer [17 genes]
Prostate cancer is a clinically and genetically heterogeneous disease with hereditary factors that are estimated to represent between 40-50% of cases, which include rare to medium high penetrance genetic variants and common low penetrance genetic variants. In particular, it has been demonstrated that HOXB13 and BRCA2 mutations increase the risk of prostate cancer. Mutations in BRCA2 would be responsible for 1-2% of early prostate tumors, conferring a higher risk of suffering prostate cancer at earlier ages (<65 years). Other syndromes associated with a higher risk of prostate cancer exist, among which Lynch syndrome stands out.
The genetic study can help carry out a correct differential diagnosis of the pathology and, therefore, not only guide the treatment but also provide a better prognosis approximation. Our recommendation includes a panel of multiple genes taking into account the different syndromes associated with both hereditary prostate cancer and hereditary renal cancer.
Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.